Phase III study of Phlai capsules in the treatment of allergic rhinitis: A randomized, double-blind, placebo-controlled trial
Asian Pacific Journal of Allergy and Immunology · 2023
DOI: 10.12932/ap-090223-1541 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Asian Pacific Journal of Allergy and Immunology, 2023. Verfasst von Minh P Hoang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. Hauptthemen laut MEDLINE: Rhinitis, Allergic, Zingiberaceae. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
BACKGROUND: Preclinical studies demonstrated anti-inflammatory effects of Zingiber montanum (J.König) Link ex Dietr.(Phlai). However, its clinical effect on allergic rhinitis (AR) is not evident. OBJECTIVE: We sought to assess the efficacy and safety of Phlai for treating AR. METHODS: A phase 3, randomized, double-blind, placebo-controlled study was conducted. Patients with AR were randomized into three groups and received Phlai 100 mg or Phlai 200 mg or placebo once a day for four weeks. The primary outcome was a change in the reflective total five symptom score (rT5SS). The secondary outcomes were the change in the instantaneous total five symptom score (iT5SS), the reflective individual symptom scores (rhinorrhea, nasal congestion, sneezing, itchy nose, itchy eyes), Rhinoconjunctivitis Quality of Life-36 Questionnaire (RCQ-36) score, peak nasal inspiratory flow (PNIF), and adverse events. RESULTS: Two hundred and sixty-two patients were enrolled. Compared with placebo, Phlai 100 mg improved rT5SS [adjusted mean difference (aMD) -0.62; 95%CI -1.22, -0.03; p = 0.039], rhinorrhea (aMD -0.19; 95%CI -0.37, 0.002; p = 0.048), itchy nose (aMD -0.24; 95%CI -0.43, -0.05; p = 0.011), and itchy eyes (aMD -0.19; 95%CI -0.36, -0.02; p = 0.033) at week 4. Nasal obstruction, sneezing, iT5SS, overall RCQ-36 score, PNIF did not reach statistical significance. Phlai 200 mg did not bring additional benefits compared to 100 mg. Adverse events were similar among groups. CONCLUSIONS: Phlai was safe. At four weeks, there were small improvements in rT5SS, together with the individual symptoms of rhinorrhea, itchy nose, and itchy eyes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Otolaryngology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
- Endoscopic Nasal and Sinus Surgery Excellent Center, King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
- Department of Otolaryngology, Hue University of Medicine and Pharmacy, Hue University, Hue, Vietnam.
- Center of Excellence in Otolaryngology-Head & Neck Surgery, Rajavithi Hospital, Bangkok, Thailand.
- Department of Otolaryngology, College of Medicine, Rangsit University, Bangkok, Thailand.
- Department of Otolaryngology, Phramongkutklao Hospital, Bangkok, Thailand.
Zitieren
APA
Hoang, M. P., Seresirikachorn, K., Chitsuthipakorn, W., Samuthpongtorn, J., Prasittivatechakool, K., Tantilipikorn, P., Poachanukoon, O., Kasemsiri, P., Kirtsreesakul, V., Kanjanaumporn, J., Aeumjaturapat, S., Chusakul, S., & Snidvongs, K. (2023). Phase III study of Phlai capsules in the treatment of allergic rhinitis: A randomized, double-blind, placebo-controlled trial. Asian Pacific Journal of Allergy and Immunology. https://doi.org/10.12932/ap-090223-1541
Vancouver
Hoang MP, Seresirikachorn K, Chitsuthipakorn W, Samuthpongtorn J, Prasittivatechakool K, Tantilipikorn P, et al. Phase III study of Phlai capsules in the treatment of allergic rhinitis: A randomized, double-blind, placebo-controlled trial. Asian Pacific Journal of Allergy and Immunology. 2023. doi:10.12932/ap-090223-1541
BibTeX
@article{Hoang2023,
author = {Hoang, Minh P and Seresirikachorn, Kachorn and Chitsuthipakorn, Wirach and Samuthpongtorn, Jompol and Prasittivatechakool, Kajohnkiat and Tantilipikorn, Pongsakorn and Poachanukoon, Orapan and Kasemsiri, Pornthep and Kirtsreesakul, Virat and Kanjanaumporn, Jesada and Aeumjaturapat, Songklot and Chusakul, Supinda and Snidvongs, Kornkiat},
title = {Phase III study of Phlai capsules in the treatment of allergic rhinitis: A randomized, double-blind, placebo-controlled trial},
journal = {Asian Pacific Journal of Allergy and Immunology},
year = {2023},
doi = {10.12932/ap-090223-1541}
}
EUVIMED